A., A. (2024). OUTCOME OF SUBCYCLO DIODE LASER TRANSSCLERAL CYCLOPHOTOCOAGULATION FOR TREATMENT OF GLAUCOMA. Egyptian Journal of Clinical Ophthalmology, 7(1), 63-68. doi: 10.21608/ejco.2024.361190
Aldghaimy, A.. "OUTCOME OF SUBCYCLO DIODE LASER TRANSSCLERAL CYCLOPHOTOCOAGULATION FOR TREATMENT OF GLAUCOMA". Egyptian Journal of Clinical Ophthalmology, 7, 1, 2024, 63-68. doi: 10.21608/ejco.2024.361190
A., A. (2024). 'OUTCOME OF SUBCYCLO DIODE LASER TRANSSCLERAL CYCLOPHOTOCOAGULATION FOR TREATMENT OF GLAUCOMA', Egyptian Journal of Clinical Ophthalmology, 7(1), pp. 63-68. doi: 10.21608/ejco.2024.361190
A., A. OUTCOME OF SUBCYCLO DIODE LASER TRANSSCLERAL CYCLOPHOTOCOAGULATION FOR TREATMENT OF GLAUCOMA. Egyptian Journal of Clinical Ophthalmology, 2024; 7(1): 63-68. doi: 10.21608/ejco.2024.361190
OUTCOME OF SUBCYCLO DIODE LASER TRANSSCLERAL CYCLOPHOTOCOAGULATION FOR TREATMENT OF GLAUCOMA
Ophthalmology dept., Faculty of Medicine, South Valley, Univ., Egypt,
Abstract
Purpose: The purpose of this study was to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) for the treatment of glaucoma in patients whose condition was not controlled with maximum tolerated antiglaucoma drugs or who were unable to adhere to medication regimens. Methods: This prospective interventional study included 30 eyes from 22 patients treated at the Ophthalmology Department of Qena University Hospital between January 2023 and January 2024. Patients underwent MP-TSCPC using the SubCyclo Vitra 810 laser. Baseline and follow-up assessments at 1 week, 2 weeks, 1 month, 3 months, and 6 months included intraocular pressure (IOP) measurements, best-corrected visual acuity (BCVA), and the number of antiglaucoma drugs used. Success was defined as achieving an IOP between 6 and 21 mmHg with or without antiglaucoma drugs, or a reduction in IOP of at least 20% from baseline. Results: The mean age of participants was 55.93 years, with an equal distribution of male and female patients. The majority (70%) had open-angle glaucoma. The mean number of antiglaucoma drugs significantly decreased from 3.17 ± 0.93 at baseline to 1.20 ± 1.22 at 6 months (p < 0.0001). Baseline IOP was 26.7 ± 3.18 mmHg, which significantly reduced to 16.87 ± 2.23 mmHg at 6 months (p < 0.0263). BCVA remained stable throughout the study period. The success rate was 86.67%, with minimal complications observed. Conclusion: MP-TSCPC is an effective and safe treatment modality for glaucoma, particularly for patients with difficulty adhering to medication or those unwilling to undergo invasive surgery. The procedure significantly reduces IOP and the need for antiglaucoma medications while preserving visual acuity with minimal complications.
View on SCiNiTO
Top